Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SPACE

Financiado

Precision oncology of spatial immune escape mechanisms in ovarian cancer

Tumor progression is dependent on the ability of malignant cells to escape the recognition and attack by the host immune system. The development of more efficient cancer immunotherapies has been hampered by the perplexity of immun... ver más

31/01/2028

HELSINGIN YLIOPIST...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

HELSINGIN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-01-27

ERC-2022-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

HELSINGIN YLIOPISTO

2.37M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CAN-IT-BARRIERS Disruption of systemic and microenvironmental barriers to i... 3M€ Cerrado

immunoMet Deciphering immune evasion mechanisms of metastatic cancer c... 184K€ Cerrado

EXPAND IT EXPANDing Immune Cells and their Tumor Antigens during check... 3M€ Cerrado

MIMIC Molecular mimicry as a key parameter shaping T cell immunity 2M€ Cerrado

NeoIDC Neoantigen Identification with Dendritic Cell Reprogramming 150K€ Cerrado

PLEC2022-009241 Manipulación de la replicación tumor para resensibilizar fre... 340K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2023-01-27
Fecha Fin: 2028-01-31

Líder del proyecto

HELSINGIN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Tumor progression is dependent on the ability of malignant cells to escape the recognition and attack by the host immune system. The development of more efficient cancer immunotherapies has been hampered by the perplexity of immune escape mechanisms. I hypothesize that tumor genetic drivers dictate the immune escape mechanisms, and that these mechanisms can be exploited to develop more effective immunotherapeutic strategies for patients with high-grade serous ovarian cancer (HGSC), the most common and lethal ovarian cancer. My group has developed an optimized algorithm based on homologous recombination (HR) DNA repair deficiency to enable clinically meaningful stratification of the complex HGSC genotypes. We will define the immunogenicity of the HGSC genotypes via profiling tumor somatic mutations and neoantigens, the cell-type specific gene expressions, and T/B cell receptor diversities using altogether >600 HGSC samples. Using a cutting-edge highly multiplexed technology and advanced image analysis, we will reveal the single-cell spatial landscapes of the tumor microenvironment in 200 immunogenetically-defined HGSCs. We will apply pioneering spatial analyses on the single-cell data and use artificial intelligence to uncover clinically relevant spatial biology of HGSCs. Via transcriptomic profiling of 384 spatial microregions, we will discover the detailed immune-escape mechanisms of the HGSC genotypes. For functional testing, we have developed a groundbreaking method to establish immune-competent patient-derived organoids (iPDOs), which faithfully recapitulate the patients' tumors. Using our high-throughput iPDO functional platform, we will test mechanism-specific immunotherapeutic approaches and capture the treatment responses at single-cell resolution. The discovery and functional targeting of the immune escape mechanisms gives us unprecedented potential to open new horizons in immunotherapeutic targeting of HGSC.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores